Midostaurin: Phase III data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Product: Midostaurin ( PKC412, CGP 41251)
Business: Cancer
Molecular target: FMS-like tyrosine kinase 3 (FLT3) (CD135); Stem cell factor (SCF)

Read the full 267 word article

User Sign In